Skip to content

Pathomic prediction of neoadjuvant therapy for colorectal cancer

Pathomic prediction of neoadjuvant therapy for colorectal cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098588
Enrollment
Unknown
Registered
2025-03-11
Start date
2024-04-12
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Research group:None
Control group:None

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old; 2. Colorectal adenocarcinoma was confirmed by tumor biopsy; 3. Surgical resection of the primary tumor after standard course of neoadjuvant therapy; 4. Patient's ECOG PS score was 0-1.

Exclusion criteria

Exclusion criteria: 1. Clinical data and follow-up data were missing and could not be traced. 2.The history and treatment history of active malignant tumors in other systems were also combined.; 3. The history of immune system deficiency; 4. Received other forms of anti-tumor therapy before neoadjuvant therapy; 5. Neoadjuvant therapy did not conform to the standardized diagnosis and treatment scheme; 6. Pathological response outcome to neoadjuvant therapy could not be assessed.

Design outcomes

Primary

MeasureTime frame
Tumor regression grade;

Secondary

MeasureTime frame
Progression-free survival;Overall survival;

Countries

China

Contacts

Public ContactNie Xiu

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

whunhpath@163.com+86 153 3717 7785

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026